Anupriya Agarwal

Anupriya Agarwal is a leading researcher in leukemia pathobiology, focusing on identifying genetic and environmental drivers of disease progression, drug resistance, and therapeutic discovery. Her work integrates functional assays with single-cell omics approaches to dissect mechanisms underlying preleukemic and leukemic states. Key research interests include tumor microenvironment interactions, epigenetic regulation, and drug resistance pathways in acute myeloid leukemia (AML) and other myeloid malignancies. She holds a Ph.D. from Dr. R.M.L. Avadh University and is actively involved in translational research to develop novel therapies.

Education:

• B.S., 1996, C.C.S. University
• M.S., 1998, G.B. Pant University
• Ph.D., 2003, Dr. R.M.L. Avadh University

Her research explores how genetic mutations (e.g., FLT3-ITD, TET2, RUNX1) interact with inflammatory pathways and cytokines like IL-1β to drive leukemogenesis and treatment resistance. Recent work highlights the role of CD74 signaling in RUNX1-related disorders and the therapeutic potential of targeting CCL2/CCR2 or CEBPB/IL-1β feedback loops. Her lab employs proteogenomic and phosphoproteomic strategies to predict drug responses and uncover actionable targets.

Publications span over 20 peer-reviewed articles since 2019, with a focus on AML drug resistance, epigenetic reprogramming, and biomarker discovery. Notable collaborations include studies on combination therapies with venetoclax and ibrutinib, as well as functional assays for RUNX1 variant classification. Her work bridges basic science and clinical application, emphasizing precision medicine approaches for hematologic cancers.